CTRI/2022/09/045585
Completed
Phase 4
A prospective, multicenter, open label clinical trial to evaluate efficacy and safety of Vestige Spirulina capsules in overall immunity of Healthy subjects.
Vestige Marketing Pvt Ltd0 sites50 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Vestige Marketing Pvt Ltd
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subject is willing and able to give written informed consent.
- •2\. Aged 18\-65 years of age
- •3\. Healthy Men and non\-pregnant women
- •4\. Subject is willing, able, and likely to comply with all study procedures and
- •restrictions.
Exclusion Criteria
- •1\. Current or 12 months prior to screening severe cardiovascular diseases, including: NYHA Class III or IV chronic heart failure, clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction, heart and coronary vessel surgery, significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure \>180 mm Hg and diastolic blood pressure \>110 mm Hg, pulmonary embolism or deep vein thrombosis.
- •2\. Type 1 diabetes mellitus and uncontrolled type 2 diabetes mellitus (HbA1c \> 10\.5 %, fasting plasma glucose \>270 mg/dl at screening or episodes of severe hypoglycemia 1 month prior to screening);
- •3\. Severe diseases of the central nervous system, including seizures in history or conditions that may lead to their development; stroke or transient ischemic attack within 12 months prior to screening; head injuries or loss of consciousness within 12 months prior to screening; a brain tumor.
- •4\. Significant uncontrolled concomitant disease, such as neurological, renal, hepatic, endocrine and gastrointestinal which according to the Investigator, could prevent the patient from participating in the study.
- •5\. Participation in other clinical studies or administration of investigational products within 4 weeks prior to screening.
- •6\. HIV, active viral (hepatitis B and C) or a cirrhotic liver disease in medical history.
- •7\. Malignancies within the last 5 years (except for basal cell carcinoma of the skin and cervical cancer in situ that had undergone surgical removal or treatment).
- •8\. Drug or alcohol abuse at the time of screening or in the past which, in the opinion of the Investigator, makes the patient unsuitable for participation in the study.
- •9\. Pregnant or lactating women or women planning a pregnancy during the clinical study.
- •10\. Inability to read or write, unwillingness to understand and follow procedures of study protocol, as well as any other concomitant medical or serious mental conditions that make the patient unfit to participate in the study, limit the legality of obtaining informed consent or can affect patient’s ability to participate in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Assessment of efficacy and safety of Lipid based Amphotericin B gel 0.1% (Amfy gel®) in patients with moderate to severe vulvovaginal candidiasisCTRI/2014/02/004409Intas Pharmaceuticals Ltd60
Recruiting
Phase 2
To assess safety and performance of Melangeâ?¢ BRS Sirolimus Eluting BioResorbable Peripheral Scaffold System for Percutaneous Transluminal Renal Angioplasty of atherosclerotic new or restenotic lesion of the renal arteryHealth Condition 1: I701- Atherosclerosis of renal arteryCTRI/2017/10/010120Meril Life Sciences Pvt Ltd
Recruiting
N/A
A Multi-Center, Prospective, Open Label Clinical Trial to Evaluate Impact of Extended Electrocardiographic Monitoring Using MEMO Patch Plus in Patients with Acute Heart FailureDiseases of the circulatory systemKCT0008650Asan Medical Center60
Completed
Phase 4
Amla capsules in improving Overall healthCTRI/2022/09/045192Vestige Marketing Pvt Ltd50
Completed
Phase 4
clinical trail to evaluate efficacy and safety of Vestige Noni capsules in improving Overall health of healthy population.CTRI/2022/09/045314Vestige Marketing Pvt Ltd50